Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641592 | 0.81 | MET (0.47) | METFAAHUSP1PIK3CAPIK3CG | |
| SCHEMBL14641598 | 0.81 | MET (0.57) | METFAAHUSP1 | |
| SCHEMBL14641560 | 0.75 | MET (0.50) | METUSP1 | |
| SCHEMBL14641559 | 0.75 | MET (0.49) | METLSSCACNA1B | |
| SCHEMBL14641594 | 0.74 | MET (0.49) | METLSSCACNA1BPIK3CAPIK3CG | |
| SCHEMBL14641600 | 0.74 | MET (0.50) | METFAAHLSSCACNA1BPIK3CA | |
| SCHEMBL14641766 | 0.73 | MET (0.51) | METFAAHUSP1CACNA1BPIK3CA | |
| SCHEMBL14641603 | 0.73 | MET (0.47) | METFAAHCACNA1BPIK3CAPIK3CG | |
| SCHEMBL1301780 | 0.73 | MET (0.56) | METLSSPIK3CAPIK3CG | |
| SCHEMBL14641602 | 0.72 | MET (0.49) | METCACNA1BBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150551-B1 | 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2013-01-16 | — | — | EP | disclosed |